@entity2903 -induced modification of the CXC chemokine network in experimental XXXX .

@entity1 @entity2904 @entity11 @entity816 @entity10149 @entity2903 @entity687 @entity204 @entity463 @entity10150 @entity3271
CXCL chemokines display important roles in @entity463 ( @entity463 ) biology, including cell proliferation, @entity204 and migration features. While @entity2903 ( @entity2904 ) represents the standard chemotherapeutic used to treat @entity463 @entity1 , its role in CXCL networking in GBMs remains unexplored. The effects of short-term and long-term in  vitro treatment with @entity2903 on CXCL chemokine expression were characterized in @entity1 @entity11 cell lines. U373 and T98G @entity816 and @entity1 @entity3271 cells were cultured for months in the presence of increasing concentrations of @entity2904 (up to 1 mM), and their whole genome profiles were analyzed along with a complete mapping of all CXCL chemokines and their respective receptor mRNAs. The study was extended to an additional established cell line and four primocultures. The in vitro results were compared with a clinical series of 156 @entity1 @entity11 and 23 normal brain tissue samples. The expression and secretion of @entity10149 , @entity10150 and @entity687 following different @entity2904 treatments were determined in @entity1 , U373 and T98G @entity11 cells. The long-term @entity2904 -treated @entity816 cells, but not the @entity1 @entity3271 cells, developed in vivo a certain level of resistance to @entity2904 , which correlated with the up- regulation of @entity10149 , @entity10150 and @entity687 expression in the U373 and T98G @entity816 cells. The transient down-regulation of @entity10149 in @entity1 @entity11 cells using siRNA markedly impaired their proliferation rate. In conclusion, @entity2904 affects the expression and secretion of @entity10149 (and, to a lesser extent, @entity10150 and @entity687 ) in @entity11 cells, and @entity10149 directly impacts @entity11 cell biology.
